BERTAGLIA, VALENTINA
 Distribuzione geografica
Continente #
NA - Nord America 3.131
AS - Asia 2.095
EU - Europa 1.935
SA - Sud America 219
OC - Oceania 75
AF - Africa 33
Continente sconosciuto - Info sul continente non disponibili 8
Totale 7.496
Nazione #
US - Stati Uniti d'America 2.999
CN - Cina 762
IT - Italia 528
SG - Singapore 509
JP - Giappone 208
DE - Germania 207
GB - Regno Unito 176
FR - Francia 162
BR - Brasile 136
VN - Vietnam 131
SE - Svezia 110
FI - Finlandia 109
IE - Irlanda 107
CA - Canada 101
IN - India 96
AT - Austria 91
HK - Hong Kong 87
UA - Ucraina 75
ES - Italia 73
KR - Corea 68
AU - Australia 66
NL - Olanda 61
PL - Polonia 49
TW - Taiwan 47
BE - Belgio 30
GR - Grecia 30
ID - Indonesia 28
CH - Svizzera 22
RU - Federazione Russa 22
TR - Turchia 22
BD - Bangladesh 20
CL - Cile 20
AR - Argentina 18
MX - Messico 18
CO - Colombia 16
IQ - Iraq 14
JO - Giordania 14
PT - Portogallo 14
RO - Romania 12
TH - Thailandia 12
PK - Pakistan 11
IL - Israele 10
PE - Perù 10
EC - Ecuador 9
HR - Croazia 9
HU - Ungheria 9
NZ - Nuova Zelanda 9
EU - Europa 8
LB - Libano 8
PH - Filippine 8
DK - Danimarca 7
EG - Egitto 6
NO - Norvegia 6
VE - Venezuela 6
ZA - Sudafrica 6
IR - Iran 5
MO - Macao, regione amministrativa speciale della Cina 5
SI - Slovenia 5
CZ - Repubblica Ceca 4
LT - Lituania 4
SK - Slovacchia (Repubblica Slovacca) 4
HN - Honduras 3
KE - Kenya 3
MY - Malesia 3
NG - Nigeria 3
PS - Palestinian Territory 3
PY - Paraguay 3
SY - Repubblica araba siriana 3
AM - Armenia 2
BY - Bielorussia 2
CG - Congo 2
CY - Cipro 2
EE - Estonia 2
GH - Ghana 2
JM - Giamaica 2
KW - Kuwait 2
MA - Marocco 2
OM - Oman 2
RS - Serbia 2
SA - Arabia Saudita 2
SN - Senegal 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AG - Antigua e Barbuda 1
AO - Angola 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BF - Burkina Faso 1
BG - Bulgaria 1
BH - Bahrain 1
BJ - Benin 1
CU - Cuba 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LK - Sri Lanka 1
Totale 7.486
Città #
Singapore 322
Ashburn 240
Chandler 215
Beijing 182
San Jose 156
Santa Clara 147
Fairfield 133
Redwood City 113
Dublin 101
Tokyo 100
Houston 99
Wilmington 88
Dallas 84
Vienna 79
Woodbridge 72
Seattle 66
Shanghai 65
Turin 64
Nyköping 61
Helsinki 60
Torino 56
Guangzhou 55
Cambridge 48
Munich 45
Ann Arbor 44
London 42
Los Angeles 42
New York 41
Seoul 41
Milan 39
Nanjing 36
Jacksonville 33
Pisa 33
Dong Ket 32
Chengdu 30
Hefei 30
Villeurbanne 30
Hong Kong 28
Hanoi 27
Lauterbourg 27
Ho Chi Minh City 26
Columbus 25
Warsaw 25
Boston 24
Princeton 24
Medford 23
Taipei 23
Toronto 23
Wuhan 23
São Paulo 22
Jakarta 20
Bengaluru 19
Buffalo 19
Chicago 19
The Dalles 19
Turku 18
Council Bluffs 17
Düsseldorf 17
Fremont 17
Paris 16
Athens 15
Brussels 15
Central 15
Hangzhou 15
Amman 14
Boardman 14
Nuremberg 14
Raritan 14
Changsha 13
Dearborn 13
Manchester 13
Montreal 13
Québec 13
Atlanta 12
Orem 12
Rome 12
Phoenix 11
San Francisco 11
Santiago 11
Tianjin 11
Central District 10
Duncan 10
Jinan 10
Washington 10
Frankfurt am Main 9
Lappeenranta 9
Montréal 9
Mumbai 9
Shenyang 9
Sydney 9
Amsterdam 8
Bologna 8
Chongqing 8
Denver 8
Evanston 8
Memphis 8
Salt Lake City 8
San Diego 8
Vancouver 8
Zhengzhou 8
Totale 4.060
Nome #
Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer 1.339
Addition of docetaxel to androgen deprivation therapy for patients with hormone-sensitive metastatic prostate cancer: A systematic review and meta-analysis 1.334
Skeletal metastases and impact of anticancer and bone-targeted agents in patients with castration-resistant prostate cancer 656
A systematic review and meta-analysis of trials assessing PD-1/PD-L1 immune checkpoint inhibitors activity in pre-treated advanced stage malignant mesothelioma 382
The fat body mass increase after adjuvant androgen deprivation therapy is predictive of prostate cancer outcome 334
Retrospective study testing next generation sequencing of selected cancer-associated genes in resected prostate cancer 232
Biological and clinical effects of abiraterone on anti-resorptive and anabolic activity in bone microenvironment 208
18F-FDG Pet Parameters and Radiomics Features Analysis in Advanced Nsclc Treated with Immunotherapy as Predictors of Therapy Response and Survival 205
C28Sequencing cabazitaxel and new generation hormonal treatments in metastatic castration resistant prostate cancer patients after first line docetaxel: a retrospective analysis 201
Comparing T Cell Subsets in Broncho-Alveolar Lavage (BAL) and Peripheral Blood in Patients with Advanced Lung Cancer 181
Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey 175
Immune-checkpoint inhibition in stage III unresectable NSCLC: Challenges and opportunities in the post-PACIFIC era 167
SARS-CoV-2 Infection in Cancer Patients: A Picture of an Italian Onco-Covid Unit 164
An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer 158
Effects of Serum Testosterone Levels After 6 Months of Androgen Deprivation Therapy on the Outcome of Patients With Prostate Cancer. 135
Performing oncological procedures during COVID-19 outbreak: a picture from an Italian cancer center 134
Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. 133
Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon 132
PROGNOSTIC ROLE OF SERUM TESTOSTERONE LEVELS IN PROSTATE CANCER PATIENTS DURING ANDROGEN-DEPRIVATION THERAPY 128
Oncological Procedures and Risk Assessment of COVID-19 in Thoracic Cancer Patients: A Picture From an Italian Cancer Center 125
Prognostic impact of pretreatment neutrophil-to-lymphocyte ratio in castration-resistant prostate cancer patients treated with first-line docetaxel 122
Is there any place for immune-checkpoint inhibitors in the treatment algorithm of fusion-driven non-small cell lung cancer?-a literature review 121
Oligoprogressive Disease With SCLC Transformation in EGFR-Mutated NSCLC: How Biology Knowledge Can Change the Game Rules 106
Short-Term Safety and Psychosocial Impact of the BNT162b2 mRNA COVID-19 Vaccine in Cancer Patients-An Italian Single-Center Experience 103
Exploring the Potential of Non-Coding RNAs as Liquid Biopsy Biomarkers for Lung Cancer Screening: A Literature Review 100
Adjuvant chemotherapy for resected triple negative breast cancer patients: A network meta-analysis 100
Third line scenario in advanced non-small cell lung cancer: Is the anti-angiogenetic strategy the only actor up to now? 93
Optimizing the clinical management of EGFR-mutant advanced non-small cell lung cancer: a literature review 88
Chemotherapy plus immunotherapy as first line combination in older patients with extensive stage small cell lung cancer: A systematic review and meta-analysis 86
null 82
Role of osimertinib plus brain radiotherapy versus osimertinib single therapy in EGFR-mutated Non-Small-Cell Lung Cancer with brain metastases: a meta-analysis and systematic review 81
Malignant Pleural Mesothelioma: Staging and Radiological Response Criteria in Patients Treated with Immune Checkpoint Inhibitors 23
Results from a multicenter Italian observational prospective study of Pathologic Units from the “Rete Oncologica Piemonte e Valle d’Aosta” and further Italian centers looking at molecular alterations in advanced non-small cell lung cancer patients in a crucial time window 22
Infections in lung cancer patients undergoing immunotherapy and targeted therapy: an overview on the current scenario 16
null 7
Totale 7.673
Categoria #
all - tutte 20.283
article - articoli 0
book - libri 0
conference - conferenze 941
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.224


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021102 0 0 0 0 0 0 0 0 0 0 0 102
2021/2022607 46 41 39 50 47 30 47 45 38 51 119 54
2022/2023829 61 95 29 83 49 162 48 82 84 27 75 34
2023/2024479 62 72 29 46 40 41 8 37 10 39 57 38
2024/20251.028 23 45 54 84 225 92 42 43 102 92 100 126
2025/20261.772 224 122 124 211 185 95 270 90 164 142 115 30
Totale 7.673